作者: Peter J. Hotez , Ulrich Strych , Sara Lustigman , Maria Elena Bottazzi
DOI: 10.1016/J.VACCINE.2016.03.112
关键词: Environmental health 、 Immunology 、 Licensure 、 Poverty 、 Innovative financing 、 Schistosomiasis 、 Developing country 、 Lymphatic filariasis 、 Public health 、 Medicine 、 Neglected tropical diseases
摘要: Helminth infections are the most common afflictions of humankind, affecting almost every single person living in profound poverty. Through mass drug administration (MDA) we have seen sharp declines global prevalence some helminth infections, including lymphatic filariasis, onchocerciasis, and ascariasis. However, since 1990, there has been no appreciable decrease hookworm infection, schistosomiasis, or food-borne trematodiases. activities a non-profit product development partnerships two research institutes, total five human anthelmintic vaccines for infection (two) schistosomiasis (three) advanced from discovery through manufacture now Phase 1 clinical testing. At least three additional antigens, onchocerciasis one also advancing preclinical with intention moving into clinic soon. These preventive could be used as stand-alone technologies administered to infants part Expanded Program on Immunization (EPI), together drugs programs linked MDA. Significant hurdles though hinder advancement these later-stage licensure. They include absence major pharma partner (and resultant access adjuvants industrial scale manufacturing expertise), an uncharted roadmap how introduce appropriate health systems, uncertain regulatory strategies that might need rely developing country vaccine manufacturers national authorities, lack innovative financing schemes. public economic benefits introducing massive therefore deserve international attention support.